MRSN vs. CYBN, CRBP, BTMD, NKTX, SAVA, CLYM, AVTX, GLSI, CRDF, and IVVD
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Cybin (CYBN), Corbus Pharmaceuticals (CRBP), biote (BTMD), Nkarta (NKTX), Cassava Sciences (SAVA), Climb Bio (CLYM), Avalo Therapeutics (AVTX), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), and Invivyd (IVVD). These companies are all part of the "pharmaceutical products" industry.
Mersana Therapeutics vs. Its Competitors
Mersana Therapeutics (NASDAQ:MRSN) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.
Cybin has lower revenue, but higher earnings than Mersana Therapeutics. Cybin is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cybin has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%. Mersana Therapeutics' return on equity of 0.00% beat Cybin's return on equity.
Mersana Therapeutics currently has a consensus target price of $56.60, indicating a potential upside of 583.57%. Cybin has a consensus target price of $85.00, indicating a potential upside of 1,298.03%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Mersana Therapeutics.
Mersana Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
In the previous week, Mersana Therapeutics and Mersana Therapeutics both had 1 articles in the media. Mersana Therapeutics' average media sentiment score of 0.00 equaled Cybin'saverage media sentiment score.
93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Cybin beats Mersana Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MRSN) was last updated on 10/5/2025 by MarketBeat.com Staff
Free MRSN Stock Alerts